• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

28.64 +0.97 (+3.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,327,424
Open 27.69
Bid (Size) 27.41 (100)
Ask (Size) 28.61 (100)
Prev. Close 27.67
Today's Range 27.63 - 29.14
52wk Range 15.35 - 36.44
Shares Outstanding 79,199,501
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances ↗
May 20, 2026
Beam Therapeutics (NASDAQ:BEAM) Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics... 
Via MarketBeat
Topics Intellectual Property
News headline image
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
May 18, 2026
Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and Reduction in Human Neutrophil Elastase Activity... 
From Beam Therapeutics
Via GlobeNewswire

Performance

YTD
+5.5%
+5.5%
1 Month
-5.0%
-5.0%
3 Month
+1.1%
+1.1%
6 Month
+21.3%
+21.3%
1 Year
+70.2%
+70.2%

More News

Read More
News headline image
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗
May 18, 2026
Via The Motley Fool
BEAM Stock In Focus As FDA Alignment Wins William Blair’s Praise ↗
January 12, 2026
Via Stocktwits
News headline image
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
May 13, 2026
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
May 12, 2026
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
May 07, 2026
From Beam Therapeutics
Via GlobeNewswire
News headline image
3 Biotech Stocks That Could Benefit from the Patent Cliff ↗
April 27, 2026
Via MarketBeat
Topics Intellectual Property
News headline image
Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors. ↗
April 11, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
April 02, 2026
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
April 01, 2026
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
March 25, 2026
From Beam Therapeutics
Via GlobeNewswire
News headline image
What's Going On With Beam Therapeutics Stock? ↗
February 24, 2026
Via Benzinga
News headline image
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
February 24, 2026
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
February 24, 2026
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program
February 23, 2026
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Senior Vice President Sells 6,198 Shares for $216,933 ↗
February 01, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Nasdaq, S&P 500 Futures Climb Ahead Of Apple Earnings: Why META, TSLA, MP, CRML, SER Are On Traders' Radar Today ↗
January 29, 2026
Via Stocktwits
Topics Artificial Intelligence ETFs Government
Top stock movements in today's session. ↗
January 12, 2026
Via Chartmill
News headline image
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
January 11, 2026
From Beam Therapeutics
Via GlobeNewswire
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
December 31, 2025
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
December 06, 2025
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics (BEAM) Earnings Transcript ↗
November 27, 2025
Via The Motley Fool
Topics Death
News headline image
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
November 12, 2025
From Beam Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Beam Therapeutics Inc. - Common Stock publicly traded?
Yes, Beam Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Beam Therapeutics Inc. - Common Stock trade on?
Beam Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Beam Therapeutics Inc. - Common Stock?
The ticker symbol for Beam Therapeutics Inc. - Common Stock is BEAM on the Nasdaq Stock Market
What is the current price of Beam Therapeutics Inc. - Common Stock?
The current price of Beam Therapeutics Inc. - Common Stock is 28.64
When was Beam Therapeutics Inc. - Common Stock last traded?
The last trade of Beam Therapeutics Inc. - Common Stock was at 05/22/26 04:00 PM ET
What is the market capitalization of Beam Therapeutics Inc. - Common Stock?
The market capitalization of Beam Therapeutics Inc. - Common Stock is 2.27B
How many shares of Beam Therapeutics Inc. - Common Stock are outstanding?
Beam Therapeutics Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap